Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
Rhea-AI Summary
Evogene (Nasdaq: EVGN) appointed Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026. Dr. Nissan brings more than 15 years of experience across biotechnology, pharmaceutical and AI-enabled drug discovery and holds a PhD plus postdoctoral research in biochemistry and proteomics from the Weizmann Institute of Science.
Her prior roles include CEO and Co‑Founder of Protica Bio and senior R&D and management positions at EcoPhage, BiomX and Teva. Management says she will help scale Evogene's small‑molecule discovery and optimization powered by the ChemPass AI platform and expand industry collaborations.
Positive
- Appointment effective Jan 1, 2026
- Dr. Olga Nissan has 15+ years biotech/pharma experience
- Holds a PhD and postdoctoral training in biochemistry and proteomics from Weizmann
Negative
- None.
News Market Reaction
On the day this news was published, EVGN declined 3.17%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.9% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $314K from the company's valuation, bringing the market cap to $10M at that time. Trading volume was elevated at 2.7x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
REHOVOT,
Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical development, and business operations across the pharmaceutical, diagnostics, and agri-biotechnology sectors. Her prior roles include CEO and Co-Founder of Protica Bio, Technology Manager at EcoPhage, Senior Scientist at BiomX, and QC Domain Manager at Teva Pharmaceutical Industries.
Dr. Nissan holds a PhD and completed postdoctoral research in the fields of biochemistry and proteomics, from the Weizmann Institute of Science.
"I am excited to join Evogene at a pivotal time in its expansion," said Dr. Olga Nissan. "The company's commitment to translating cutting-edge, AI-driven science into meaningful small-molecule-based therapeutic value, strongly aligns with my experience across pharma and biotech. I look forward to building strategic partnerships, advancing innovative discovery programs, and working with Evogene's talented team to accelerate the delivery of impactful solutions for patients and partners worldwide."
Mr. Ofer Haviv, Evogene's President and CEO, added: "We are delighted to welcome Dr. Olga Nissan to Evogene's leadership team. With more than 15 years of experience spanning biotech, pharma, and AI-enabled drug discovery, Olga brings a unique combination of scientific depth, business development leadership, and company-building expertise. We believe her capabilities will be instrumental as we scale our small-molecule discovery and optimization offering, powered by our ChemPass AI tech-engine, and expand collaborations with leading industry partners - translating real-world innovation into meaningful value."
About Evogene:
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.
At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.
Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation".
Learn more at: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss: the success of ChemPass AI discovery and optimization efforts in drug development and Evogene's success in expanding its collaborations with leading industry partners. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between
Evogene Investors Relations Contact:
Email: ir@evogene.com
Tel: +972-8-9311901
Photo - https://mma.prnewswire.com/media/2852394/Olga_Nissan.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-announces-appointment-of-dr-olga-nissan-as-its-vice-president-of-business-development-302650634.html
SOURCE Evogene
FAQ
When does Dr. Olga Nissan start at Evogene (EVGN)?
What experience does Dr. Olga Nissan bring to Evogene (EVGN)?
How will Dr. Nissan contribute to Evogene's small‑molecule programs (EVGN)?
What academic qualifications does Dr. Olga Nissan have for her role at Evogene (EVGN)?
Which companies did Dr. Olga Nissan work at before joining Evogene (EVGN)?
Does Dr. Nissan's appointment change Evogene's leadership strategy (EVGN)?
